PDS Biotechnology Corporation - Common Stock (PDSB)
1.3300
+0.2300 (20.91%)
NASDAQ· Last Trade: May 13th, 9:23 PM EDT
Detailed Quote
Previous Close
1.100
Open
1.110
Bid
1.320
Ask
1.340
Day's Range
1.020 - 1.350
52 Week Range
0.5068 - 1.915
Volume
1,422,719
Market Cap
37.85M
PE Ratio (TTM)
-1.622
EPS (TTM)
-0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,040,153
Chart
About PDS Biotechnology Corporation - Common Stock (PDSB)
PDS Biotechnology Corp is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapy treatments for cancer and infectious diseases. The company’s proprietary technology platform aims to harness the body’s immune system to target and eliminate tumors, utilizing a novel approach that combines antigen discovery and immune system activation. With a commitment to advancing personalized medicine, PDS Biotechnology is engaged in creating therapies that seek to enhance patient outcomes and offer new hope for those battling difficult-to-treat diseases. Read More
PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce costs.
On the company’s first quarter 2026 earnings call, Chief Executive Officer Dr. Frank
PDS Biotech (PDSB) Q3 2025 earnings beat EPS estimates, sparking a major pre-market surge. The clinical-stage biotech also announced key progress for its lead cancer therapy.
The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.
Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.
